Emerging oral drug options for ulcerative colitis

References

• Ungaro R, Mehandru S, Allen PB, et al. Ulcerative colitis. Lancet. 2017;389(10080):1756–1770. doi: 10.1016/S0140-6736(16)32126-2
   PubMed Web of Science ®Google Scholar
• Torres J, Billioud V, Sachar DB, et al. Ulcerative colitis as a progressive disease: the forgotten evidence. Inflamm Bowel Dis. 2012 Jul;18(7):1356–1363. doi: 10.1002/ibd.22839
   PubMed Web of Science ®Google Scholar
• Cosnes J, Gower-Rousseau C, Seksik P, et al. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. 2011 May;140(6):1785–1794. doi: 10.1053/j.gastro.2011.01.055
   PubMed Web of Science ®Google Scholar
• Halme L, Paavola-Sakki P, Turunen U, et al. Family and twin studies in inflammatory bowel disease. World J Gastroenterol. 2006 Jun 21;12(23):3668–3672. doi: 10.3748/wjg.v12.i23.3668
   PubMed Web of Science ®Google Scholar
• Moller FT, Andersen V, Wohlfahrt J, et al. Familial risk of inflammatory bowel disease: a population-based cohort study 1977–2011. Am J Gastroenterol. 2015 Apr;110(4):564–571. doi: 10.1038/ajg.2015.50
   PubMed Web of Science ®Google Scholar
• Ananthakrishnan AN. Epidemiology and risk factors for IBD. Nat Rev Gastroenterol Hepatol. 2015 Apr;12(4):205–217. doi: 10.1038/nrgastro.2015.34
   PubMed Web of Science ®Google Scholar
• Jostins L, Ripke S, Weersma RK, et al. Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012 Nov 1;491(7422):119–124. doi: 10.1038/nature11582
   PubMed Web of Science ®Google Scholar
• UK IBD Genetics Consortium, Barrett JC, Lee JC, et al. Genome-wide association study of ulcerative colitis identifies three new susceptibility loci, including the HNF4A region. Nat Genet. 2009;41:1330–1334.
   PubMed Web of Science ®Google Scholar
• Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2017 Dec 23;390(10114):2769–2778. doi: 10.1016/S0140-6736(17)32448-0
   PubMed Web of Science ®Google Scholar
• Du L, Ha C. Epidemiology and pathogenesis of ulcerative colitis. Gastroenterol Clin North Am. 2020;49(4):643–654. doi: 10.1016/j.gtc.2020.07.005
   PubMed Web of Science ®Google Scholar
• Nakase H, Sato N, Mizuno N, et al. The influence of cytokines on the complex pathology of ulcerative colitis. Autoimmun Rev. 2022;21(3):103017. doi: 10.1016/j.autrev.2021.103017
   PubMed Web of Science ®Google Scholar
• Kobayashi T, Siegmund B, Le Berre C, et al. Ulcerative colitis. Nat Rev Dis Primers. 2020 Sep 10;6(1):74. doi: 10.1038/s41572-020-0205-x
   PubMedGoogle Scholar
• Monteleone G, Fina D, Caruso R, et al. New mediators of immunity and inflammation in inflammatory bowel disease. Curr Opin Gastroenterol. 2006;22(4):361–364. doi: 10.1097/01.mog.0000231808.10773.8e
   PubMed Web of Science ®Google Scholar
• MacDonald TT, Monteleone G. Immunity, inflammation, and allergy in the gut. Science. 2005;307(5717):1920–1925. doi: 10.1126/science.1106442
   PubMed Web of Science ®Google Scholar
• Reinisch W, Reinink AR, Higgins PD. Factors associated with poor outcomes in adults with newly diagnosed ulcerative colitis. Clin Gastroenterol Hepatol. 2015 Apr;13(4):635–642. doi: 10.1016/j.cgh.2014.03.037
   PubMed Web of Science ®Google Scholar
• Etchevers MJ, Aceituno M, O García-Bosch, et al. Risk factors and characteristics of extent progression in ulcerative colitis. Inflamm Bowel Dis. 2009 Sep;15(9):1320–1325. doi: 10.1002/ibd.20897
   PubMed Web of Science ®Google Scholar
• Marotto D, Atzeni F, Ardizzone S. et al. Extra-intestinal manifestations of inflammatory bowel diseases. Pharmacol Res. 2020;161:105206. doi: 10.1016/j.phrs.2020.105206
   PubMed Web of Science ®Google Scholar
• Beaugerie L, Itzkowitz SH, Longo DL. Cancers complicating inflammatory bowel disease. N Engl J Med. 2015 Apr 9;372(15):1441–1452. doi: 10.1056/NEJMra1403718
   PubMed Web of Science ®Google Scholar
• Raine T, Bonovas S, Burisch J, et al. ECCO guidelines on therapeutics in ulcerative colitis: medical treatment. J Crohns Colitis. 2022;16(1):2–17. doi: 10.1093/ecco-jcc/jjab178
   PubMed Web of Science ®Google Scholar
• Turner D, Ricciuto A, Lewis A, et al. STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (stride) initiative of the international organization for the study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021;160(5):1570–1583. doi: 10.1053/j.gastro.2020.12.031
   PubMed Web of Science ®Google Scholar
• Solitano V, Vuyyuru SK, MacDonald JK, et al. Efficacy and safety of advanced oral small molecules for inflammatory bowel disease: systematic review and meta-analysis. J Crohns Colitis. 2023 Jun 15;jjad100. doi: 10.1093/ecco-jcc/jjad100
   PubMed Web of Science ®Google Scholar
• Troncone E, Marafini I, Del Vecchio Blanco G, et al. Novel therapeutic options for people with ulcerative colitis: an update on recent developments with Janus kinase (JAK) inhibitors. Clin Exp Gastroenterol. 2020 May 5;13:131–139. doi: 10.2147/CEG.S208020
   PubMed Web of Science ®Google Scholar
• Colombel JF, Rutgeerts P, Reinisch W, et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology. 2011 Oct;141(4):1194–1201. doi: 10.1053/j.gastro.2011.06.054
   PubMed Web of Science ®Google Scholar
• Travis SP, Higgins PD, Orchard T, et al. Review article: defining remission in ulcerative colitis. Aliment Pharmacol Ther. 2011 Jul;34(2):113–124. doi: 10.1111/j.1365-2036.2011.04701.x
   PubMed Web of Science ®Google Scholar
• Gordon H, Biancone L, Fiorino G, et al. ECCO guidelines on inflammatory bowel disease and malignancies. J Crohns Colitis. 2023;17(6):827–854. doi: 10.1093/ecco-jcc/jjac187
   PubMed Web of Science ®Google Scholar
• Feuerstein JD, Isaacs KL, Schneider Y, et al. AGA clinical practice guidelines on the management of moderate to severe ulcerative colitis. Gastroenterology. 2020;158(5):1450–1461. doi: 10.1053/j.gastro.2020.01.006
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005 Dec 8;353(23):2462–2476. doi: 10.1056/NEJMoa050516
   PubMed Web of Science ®Google Scholar
• Pugliese D, Felice C, Papa A, et al. Anti TNF-α therapy for ulcerative colitis: current status and prospects for the future. Expert Rev Clin Immunol. 2017;13(3):223–233. doi: 10.1080/1744666X.2017.1243468
   PubMed Web of Science ®Google Scholar
• Neurath L, D’Amico F, Danese S. Emerging drugs for the treatment of moderately to severely active ulcerative colitis: review of phase II and III clinical trials. Expert Opin Emerg Drugs. 2023;28(1):27–42. doi: 10.1080/14728214.2023.2186399
   PubMed Web of Science ®Google Scholar
• Reinisch W, Sandborn WJ, Hommes DW, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut. 2011 Jun;60(6):780–787. doi: 10.1136/gut.2010.221127
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, van Assche G, W Reinisch, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012 Feb;142(2):257-65.e1–3. doi: 10.1053/j.gastro.2011.10.032
   Web of Science ®Google Scholar
• Armuzzi A, Fiorino G, Variola A, et al. The PROSIT cohort of infliximab biosimilar in IBD: a prolonged follow-up on the effectiveness and safety across Italy. Inflamm Bowel Dis. 2019;25(3):568–579. doi: 10.1093/ibd/izy264
   PubMed Web of Science ®Google Scholar
• PURSUIT-Maintenance Study Group, Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014 Jan;146(1):96–109.e1. doi: 10.1053/j.gastro.2013.06.010
   PubMed Web of Science ®Google Scholar
• Gibson PR, Feagan BG, Sandborn WJ, et al. Maintenance of efficacy and continuing safety of golimumab for active ulcerative colitis: PURSUIT-SC maintenance study extension through 1 year. Clin Transl Gastroenterol. 2016 Apr 28;7(4):e168. doi: 10.1038/ctg.2016.24
   PubMedGoogle Scholar
• Pouillon L, Bossuyt P, Peyrin-Biroulet L. Considerations, challenges and future of anti-TNF therapy in treating inflammatory bowel disease. Expert Opin Biol Ther. 2016;16(10):1277–1290. doi: 10.1080/14712598.2016.1203897
   PubMed Web of Science ®Google Scholar
• Lobatón T, Ferrante M, P Rutgeerts, et al. Efficacy and safety of anti-TNF therapy in elderly patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2015;42(4):441–451. doi: 10.1111/apt.13294
   PubMed Web of Science ®Google Scholar
• Fiorino G, Caprioli F, M Daperno, et al. National patients’ association representatives. Use of biosimilars in inflammatory bowel disease: a position update of the Italian group for the study of inflammatory bowel disease (IG-IBD). Dig Liver Dis. 2019;51(5):632–639. doi: 10.1016/j.dld.2019.02.004
   PubMedGoogle Scholar
• Kochar B, Cai W, Cagan A, et al. Pretreatment frailty is independently associated with increased risk of infections after immunosuppression in patients with inflammatory bowel diseases. Gastroenterology. 2020;158(8):2104–2111.e2. doi: 10.1053/j.gastro.2020.02.032
   PubMed Web of Science ®Google Scholar
• Singh S, Heien HC, Sangaralingham L, et al. Frailty and risk of serious infections in biologic-treated patients with inflammatory bowel diseases. Inflamm Bowel Dis. 2021;27(10):1626–1633. doi: 10.1093/ibd/izaa327
   PubMed Web of Science ®Google Scholar
• Salvatori S, Marafini I, Venuto C, et al. Frail phenotype in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2022 Dec 2;izac242. doi: 10.1093/ibd/izac242
   PubMedGoogle Scholar
• Salvatori S, Marafini I, Franchin M, et al. Reversibility of frail phenotype in patients with inflammatory bowel diseases. J Clin Med. 2023;12(7):2658. doi: 10.3390/jcm12072658
   PubMed Web of Science ®Google Scholar
• Guerra I, Algaba A, Pérez-Calle JL, et al. Induction of psoriasis with anti-TNF agents in patients with inflammatory bowel disease: a report of 21 cases. J Crohns Colitis. 2012;6(5):518–523. doi: 10.1016/j.crohns.2011.10.007
   PubMed Web of Science ®Google Scholar
• Feagan BG, Rutgeerts P, Sands BE, et al. GEMINI 1 Study Group. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369(8):699–710. doi: 10.1056/NEJMoa1215734
   PubMed Web of Science ®Google Scholar
• Wyant T, Fedyk E, Abhyankar B. An overview of the mechanism of action of the monoclonal antibody Vedolizumab. J Crohns Colitis. 2016;10(12):1437–1444. doi: 10.1093/ecco-jcc/jjw092
   PubMed Web of Science ®Google Scholar
• Zeissig S, Rosati E, Dowds CM, et al. Vedolizumab is associated with changes in innate rather than adaptive immunity in patients with inflammatory bowel disease. Gut. 2019;68(1):25–39. doi: 10.1136/gutjnl-2018-316023
   PubMed Web of Science ®Google Scholar
• Engel T, Ungar B, Yung DE, et al. Vedolizumab in IBD–lessons from real-world experience; a systematic review and pooled analysis. Journal Of Crohn’s And Colitis. 2018;12(2):245–257. doi: 10.1093/ecco-jcc/jjx143
   PubMed Web of Science ®Google Scholar
• Marafini I, Troncone E, Rocchetti I, et al. Respiratory tract infections in inflammatory bowel disease patients taking vedolizumab: a systematic review and meta-analysis of randomized controlled trials. Front Pharmacol. 2021;11:585732. doi: 10.3389/fphar.2020.585732
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sands BE, et al. The safety of vedolizumab for ulcerative colitis and Crohn’s disease. Gut. 2017;66(5):839–851. doi: 10.1136/gutjnl-2015-311079
   PubMed Web of Science ®Google Scholar
• VARSITY Study Group, Sands BE, Peyrin-Biroulet L, Loftus EV, et al. Vedolizumab versus Adalimumab for moderate-to-severe ulcerative colitis. N Engl J Med. 2019;381(13):1215–1226.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Baert F, Danese S, et al. Efficacy and safety of vedolizumab subcutaneous formulation in a randomized trial of patients with ulcerative colitis. Gastroenterology. 2020;158(3):562–572.e12. doi: 10.1053/j.gastro.2019.08.027
   PubMed Web of Science ®Google Scholar
• Ledder O, Assa A, Levine A, et al. Vedolizumab in paediatric inflammatory bowel disease: a retrospective multi-centre experience from the paediatric IBD porto group of ESPGHAN. J Crohns Colitis. 2017;11(10):1230–1237. doi: 10.1093/ecco-jcc/jjx082
   PubMed Web of Science ®Google Scholar
• Sands BE, Sandborn WJ, Panaccione R, et al. Ustekinumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2019;381(13):1201–1214. doi: 10.1056/NEJMoa1900750
   PubMed Web of Science ®Google Scholar
• Feagan BG, Sandborn WJ, Gasink C, et al. Ustekinumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2016;375(20):1946–1960. doi: 10.1056/NEJMoa1602773
   PubMed Web of Science ®Google Scholar
• Scribano ML, Aratari A, Neri B, et al. Effectiveness of ustekinumab in patients with refractory Crohn’s disease: a multicentre real-life study in Italy. Therap Adv Gastroenterol. 2022;15:17562848211072412. doi: 10.1177/17562848211072412
   Web of Science ®Google Scholar
• Sandborn WJ, Ghosh S, Panes J, et al. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med. 2012 Aug 16;367(7):616–624. doi: 10.1056/NEJMoa1112168
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Su C, Sands BE, et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;376(18):1723–1736. doi: 10.1056/NEJMoa1606910
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Lawendy N, Danese S, et al. Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE open, an open-label, long-term extension study with up to 7.0 years of treatment. Aliment Pharmacol Ther. 2022;55(4):464–478. doi: 10.1111/apt.16712
   PubMed Web of Science ®Google Scholar
• Winthrop KL, Vermeire S, Long MD, et al. Long-term risk of herpes zoster infection in patients with ulcerative colitis receiving Tofacitinib. Inflamm Bowel Dis. 2023;29(1):85–96. doi: 10.1093/ibd/izac063
   PubMed Web of Science ®Google Scholar
• Hanauer S, Panaccione R, Danese S, et al. Tofacitinib induction therapy reduces symptoms within 3 days for patients with ulcerative colitis. Clin Gastroenterol Hepatol. 2019 Jan;17(1):139–147. doi: 10.1016/j.cgh.2018.07.009
   PubMed Web of Science ®Google Scholar
• Danese S, Vermeire S, Zhou W, et al. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials. Lancet. 2022;399(10341):2113–2128. doi: 10.1016/S0140-6736(22)00581-5
   PubMed Web of Science ®Google Scholar
• Feagan BG, Danese S, Loftus EV, et al. Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial. Lancet. 2021;397(10292):2372–2384. doi: 10.1016/S0140-6736(21)00666-8
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, D’Haens G, et al. Ozanimod as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2021;385(14):1280–1291. doi: 10.1056/NEJMoa2033617
   PubMed Web of Science ®Google Scholar
• Aslam N, Lo SW, Sikafi R. Lo SW et al. A review of the therapeutic management of ulcerative colitis. Therap Adv Gastroenterol. 2022;15:1–21. doi: 10.1177/17562848221138160
   Web of Science ®Google Scholar
• Allegretti JR, Mitsialis V, Canavan JB. Low-dose IL2 UC study group; Snapper SB. Low-dose Interleukin 2 for the treatment of moderate to severe ulcerative colitis. Gastroenterology. 2023 Apr 7;S0016-5085(23):00584–X.
   Google Scholar
• Sandborn WJ, Danese S, Leszczyszyn J, et al. Oral Ritlecitinib and Brepocitinib for Moderate-to-Severe Ulcerative Colitis: Results From a Randomized, Phase 2b Study. Clin Gastroenterol Hepatol. 2023 Sep;21(10):2616–2628.e7.
   PubMed Web of Science ®Google Scholar
• Danese S, Panaccione R, D’Haens G, et al. DOP42 efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with moderately-to-severely active ulcerative colitis: 12-week results from the phase 2 LATTICE-UC study. J Crohn’s Colitis. 2022;16(Supplement_1):i091–i092. doi: 10.1093/ecco-jcc/jjab232.081
   Google Scholar
• Chen B, Zhong J, Li X, et al. Efficacy and safety of Ivarmacitinib in patients with moderate-to-severe, active, ulcerative colitis: a phase II study. Gastroenterol. 2022 Dec;163(6):1555–1568. doi: 10.1053/j.gastro.2022.08.007
   PubMed Web of Science ®Google Scholar
• https://Clinicaltrials.Gov/Ct2/Show/NCT03758443
   Google Scholar
• Sandborn WJ, Peyrin-Biroulet L, Zhang J, et al. Efficacy and safety of etrasimod in a phase 2 randomized trial of patients with ulcerative colitis. Gastroenterology. 2020;158(3):550–561. doi: 10.1053/j.gastro.2019.10.035
   PubMed Web of Science ®Google Scholar
• Vermeire S, Chiorean M, Panés J, et al. Long-term safety and efficacy of etrasimod for ulcerative colitis: results from the open-label extension of the OASIS study. J Crohn’s Colitis. 2021;15(6):950–959. doi: 10.1093/ecco-jcc/jjab016
   Google Scholar
• Sandborn WJ, Vermeire S, Peyrin-Biroulet L, et al. Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies. Lancet. 2023 Apr 8;401(10383):1159–1171. doi: 10.1016/S0140-6736(23)00061-2
   PubMed Web of Science ®Google Scholar
• https://Www.Globenewswire.Com/News-Release/2022/05/03/2435049/0/En/Connect-Biopharma-Announces-Week-12-Top-Line-Results-from-Phase-2-CBP-307-Trial-in-Patients-with-Moderate-to-Severe-Ulcerative-Colitis.Html
   Google Scholar
• Radeke HH, Stein J, Van Assche G, et al. A multicentre, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and tolerability of the S1P receptor agonist KRP203 in patients with moderately active refractory ulcerative colitis. Inflamm Intest Dis. 2020;5:180–190. doi: 10.1159/000509393
   PubMedGoogle Scholar
• Vermeire S, Hébuterne X, Tilg H, et al. Induction and long-term follow-up with ABX464 for moderate-to-severe ulcerative colitis: results of phase iia trial. Gastroenterology. 2021 Jun;160(7):2595–2598.e3. doi: 10.1053/j.gastro.2021.02.054
   PubMed Web of Science ®Google Scholar
• Vermeire S, Sands BE, Tilg H, et al. ABX464 (Obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extension. Lancet Gastroenterol Hepatol. 2022 Nov;7(11):1024–1035. doi: 10.1016/S2468-1253(22)00233-3
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Mattheakis LC, Modi NB, et al. PTG-100, an oral Α4β7 antagonist peptide: preclinical development and phase 1 and 2a studies in ulcerative colitis. Gastroenterology. 2021;161(6):1853–1864.e10. doi: 10.1053/j.gastro.2021.08.045
   PubMed Web of Science ®Google Scholar
• Yoshimura N, Watanabe M, Motoya S, et al. Safety and efficacy of AJM300, an oral antagonist of Α4 integrin, in induction therapy for patients with active ulcerative colitis. Gastroenterology. 2015;149(7):1775–1783.e2. doi: 10.1053/j.gastro.2015.08.044
   PubMed Web of Science ®Google Scholar
• Matsuoka K, Watanabe M, Ohmori T, et al. AJM300 (carotegrast methyl), an oral antagonist of Α4-integrin, as induction therapy for patients with moderately active ulcerative colitis: a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Gastroenterol Hepatol. 2022 Jul;7(7):648–657. doi: 10.1016/S2468-1253(22)00022-X
   PubMed Web of Science ®Google Scholar
• Weisshof R, Aharoni Golan M, Sossenheimer PH, et al. Real-world experience with Tofacitinib in IBD at a tertiary center. Dig Dis Sci. 2019;64(7):1945–1951. doi: 10.1007/s10620-019-05492-y
   PubMed Web of Science ®Google Scholar
• Olivera P, Danese S, Peyrin-Biroulet L. Next generation of small molecules in inflammatory bowel disease. Gut. 2017 Feb;66(2):199–209. doi: 10.1136/gutjnl-2016-312912
   PubMed Web of Science ®Google Scholar
• Ytterberg SR, Bhatt DL, Mikuls TR, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022;386(4):316–326. doi: 10.1056/NEJMoa2109927
   PubMed Web of Science ®Google Scholar
• Czarnewski P, Parigi SM, Sorini C, et al. Conserved transcriptomic profile between mouse and human colitis allows unsupervised patient stratification. Nat Commun. 2019 Jun 28;10(1):2892. doi: 10.1038/s41467-019-10769-x
   PubMedGoogle Scholar
• Furer V, Elkayam O. Dual biologic therapy in patients with rheumatoid arthritis and psoriatic arthritis. Rambam Maimonides Med J. 2023 Apr 30;14(2):e0007. doi: 10.5041/RMMJ.10494
   PubMed Web of Science ®Google Scholar